Core Insights - TeleVox is showcasing its latest innovations in patient relationship management (PRM) solutions at the HLTH annual conference, highlighting features such as AI-driven SMART SMS and Digital Care Programs aimed at reducing readmissions [1][3] - The HLTH conference is a major event for healthcare innovation, attracting over 12,000 leaders to discuss technology advancements and partnerships in the health industry [2] Company Overview - TeleVox is a leading provider of omnichannel digital patient relationship management technology, trusted by over 7,000 healthcare organizations, including hospitals and community health centers [4] - The company's platform integrates with electronic health records (EHR) to facilitate automated, personalized, two-way interactions with patients, enhancing care continuity and reducing operational burdens [4] - TeleVox has been operational for 30 years, focusing on improving healthcare communication processes and driving revenue for healthcare providers [4]

Core Viewpoint - Cue Health has announced plans to wind down its business through a Chapter 7 bankruptcy filing, leading to the termination of all employees, including executives and board members [1]. Group 1: Stock Performance - Following the bankruptcy announcement, Cue Health's stock experienced a nearly 40% decline on Wednesday, with approximately 70.9 million shares traded, significantly higher than its daily average of 9.2 million shares [2]. - Despite the bankruptcy news, Cue Health's stock rebounded by 98.9% on Thursday morning, with over 82 million shares traded during pre-market hours [2]. Group 2: Market Reactions - The volatility in Cue Health's stock is attributed to traders capitalizing on the price dip, likely buying shares to sell for profit shortly after [3]. - Caution is advised for traders considering investments in Cue Health stock, as the current rise may not be sustainable given the company's bankruptcy filing [3].

Cue Health (NASDAQ:HLTH) stock is down on Wednesday after the healthcare technology company announced plans to wind down its business. According to a press release from Cue Health, the company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code to pursue this wind-down. The company notes this comes after unsuccessful attempts to secure additional financing or a strategic transaction. To go along with this, the company has terminated all of its employees. This also includes all the exec ...

Financial Performance and Losses - The company incurred significant losses since inception, with net losses of $373.5 million and $194.1 million for the years ended December 31, 2023 and 2022, respectively, leading to an accumulated deficit of $591.5 million as of December 31, 2023[127]. - The company achieved net income of $86.4 million for the year ended December 31, 2021, marking its first profitable year, but profitability remains uncertain moving forward[127]. - The company incurred an accumulated deficit of $591.5 million as of December 31, 2023, and experienced negative cash flows during the years ended December 31, 2023 and 2022[262]. - The company expects to incur additional expenses related to workforce reduction actions, impacting its financial condition in the near term[129]. - The company may need to raise additional capital for various reasons, including funding operations, developing new products, and expanding internationally, which could lead to dilution of stockholder value[248]. Revenue Dependence and Market Risks - Revenue for the near term will almost exclusively depend on sales of the Cue COVID-19 test, which is critical for the company's success until additional tests can be commercialized[138]. - The company’s near-term success is heavily reliant on the continued commercialization and market acceptance of its Cue COVID-19 Test Kit[130]. - In 2023, a single customer accounted for approximately 57% of total product revenue, while two customers accounted for 74% in 2022, indicating significant revenue concentration risks[163]. - The U.S. Department of Defense (DoD) represented about 19% of total revenue in 2022, down from 61% in 2021 and 39% in 2020, highlighting a decline in public sector revenue reliance[140]. - The total addressable market for the Cue Integrated Care Platform may be significantly smaller than estimated, with market opportunity estimates subject to uncertainty and dependent on various assumptions[176]. Competition and Market Challenges - The diagnostic testing market is highly competitive and rapidly evolving, posing challenges for the company in evaluating its business and future prospects[126]. - The company faces intense competition from established diagnostic testing companies, including Quest Diagnostics and Abbott Laboratories, as well as emerging technology-enabled health companies[152][153]. - The sales cycle with institutional customers is lengthy and variable, making revenue forecasting challenging due to the complexity of the sales process[160]. - The company must continuously enhance its Cue Health Monitoring System and develop new tests to remain competitive and avoid obsolescence[151]. - There is a risk that the healthcare system may resist the disruptive changes proposed by the company, limiting market potential for its products[146]. Operational and Technical Risks - The company has identified material weaknesses in its internal control over financial reporting, which could affect its ability to accurately report financial conditions[124]. - The company faces difficulties in managing growth, which could adversely affect operations and financial performance[124]. - Operational and technical difficulties may harm the commercial attractiveness of products and increase costs, diverting resources from other priorities[170]. - The performance of the Cue Health Monitoring System relies on internet and mobile connectivity, with potential disruptions adversely affecting customer relationships[175]. - The company may face challenges in maintaining satisfactory pricing and margins for its Cue Test Kits due to competitive pricing pressures and reimbursement limits from third-party payors[186]. Supply Chain and Manufacturing Risks - The company relies on third parties for the manufacture of its Cue Readers and Cue Wands, increasing the risk of insufficient quantities or quality issues that could impair development efforts[271]. - The company has limited experience in manufacturing its products in commercial quantities, which may lead to production delays or interruptions[266]. - There is a global shortage of microchips that has been reported since early 2021, which may impact the company's production capabilities[280]. - The company relies on single-source suppliers for some components, exposing it to potential shortages and disruptions in the supply chain[280]. - The company may incur unexpected production disruption costs if it cannot accurately forecast and manage component purchases as production scales up[283]. Intellectual Property and Legal Risks - The patent protection for the company's products may not be sufficient to prevent competitors from developing similar technologies, which could adversely affect its business[284]. - The company may face challenges in obtaining exclusive licenses for jointly-owned patents, which could allow competitors to market similar technologies[296]. - The company may face significant financial liabilities if found to infringe third-party patents, including potential treble damages for willful infringement[303]. - Numerous third-party patents exist in the molecular diagnostic testing field, which could pose risks of infringement claims against the company[321]. - The competitive landscape in the diagnostic testing industry may lead to significant intellectual property-related litigation, impacting the commercialization of the Cue Health Monitoring System[318]. Regulatory and Compliance Risks - The company has not yet commenced negotiations for a follow-on Federal Acquisition Regulation (FAR)-based contract with the U.S. DoD, which could impact future revenue from government contracts[140]. - Compliance with U.S. and foreign export controls and anti-corruption laws is critical, as violations could lead to severe penalties and impact competitive positioning[238]. - Any failure to comply with applicable regulations by the company or its manufacturers could result in significant sanctions, adversely affecting its business[276]. - The company is subject to data protection laws, and failure to comply could result in significant legal and financial exposure[226]. - The COVID-19 pandemic has led to modifications in business practices, including employee testing and travel restrictions, which may delay clinical studies and regulatory approvals for new products[212]. Management and Workforce Risks - The company is highly dependent on its senior management team, and the loss of key personnel could significantly impact its strategic objectives[199]. - Competition for skilled personnel is intense, which may limit the company's ability to attract and retain qualified employees necessary for growth[200]. - The company currently has limited sales and marketing infrastructure and must build these capabilities to successfully commercialize its products[203]. - A workforce reduction plan was implemented in January 2024 to reduce operating expenses and adjust cash flows amid a challenging macroeconomic environment[142]. - The company has implemented a remediation plan to address internal control weaknesses, including hiring key financial personnel and enhancing documentation processes[195].

Cue Health Reports Fourth Quarter 2023 Financial Results SAN DIEGO, CA – March 13, 2024 – Cue Health Inc. ("Cue" or the "Company") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights "We made progress executing on our strategic priorities in 2023. We obtained two FDA authorizations including a de novo approval for our COVID-19 Molecular Test and an EUA for our Mpox Molecular Test, and made two de novo submissions for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40824 _________________ Cue Health Inc. (Exact Name of Registrant as Specified in its Cha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents Commission File Number: 001-40824 _________________ Cue Health Inc. (Exact Name of Registrant as Specified in its Charter) ...

Company Participants Conference Call Participants Operator Lorna Williams These risks and uncertainties include, but are not limited to, those outlined in today's call as well as other risks identified from time-to-time in our public statements and reports filed with the SEC. With that, I'd like to turn the call over to Ayub. While these results are predominantly from our COVID-19 product, we're making significant progress in our strategic plan to improve the way healthcare is delivered with diagnostic-enab ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _________________ OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 For the transition period from to Commission File Number: 001-40590 _________________ Cue Health Inc. (Exact Name of Registrant as Specified in its Charter) _________________ Delaware 27-1562193 (State or other jurisdiction of incorporation or organization ...

Financial Performance and Losses - The company incurred significant losses since inception, reporting net losses of $20.6 million and $47.4 million for the years ended December 31, 2019 and 2020, respectively, and a net loss of $194.1 million for the year ended December 31, 2022, with an accumulated deficit of $218.1 million as of the same date [128]. - The company's future profitability is uncertain and may be affected by various factors, including market acceptance of its products and the length of the COVID-19 pandemic [130]. - The company has federal and state net operating loss (NOL) carryforwards of approximately $51.9 million and $141.6 million, respectively, as of December 31, 2022 [267]. Revenue Dependence and Market Challenges - The company's revenue for the near term will almost exclusively depend on sales of its COVID-19 test, which is critical for its success [134]. - The company's revenue for the near term will almost exclusively depend on sales of its COVID-19 test, which is expected to account for almost all or the substantial majority of revenue until additional tests can be commercialized [143]. - The COVID-19 diagnostic testing market is highly competitive and rapidly evolving, making it challenging for the company to evaluate its business prospects [125]. - The diagnostic testing market is extremely competitive, with significant competition from established companies such as Quest Diagnostics and Laboratory Corporation of America, as well as emerging technology-enabled health companies [161]. Product Development and Regulatory Approvals - The company has received two Emergency Use Authorizations (EUAs) from the FDA for its COVID-19 test, but the future of these authorizations is uncertain, which could impact commercialization efforts [131]. - The company has received authorization in Canada and Singapore for its COVID-19 test, but any revocation of these authorizations could hinder market expansion [132][133]. - The company has expanded its product line to include thirteen at-home test kits for general health and wellness conditions, although there is uncertainty regarding market demand for these new offerings [128]. - The company is pursuing the development of additional tests for various health conditions, which requires substantial research and regulatory approvals [197]. Manufacturing and Supply Chain Risks - The company has limited experience manufacturing products in commercial quantities, which poses a risk to its ability to meet market demand [129]. - The company operates three manufacturing facilities for Cue Cartridges, which may face production delays due to reliance on a limited number of suppliers [273]. - The company relies on third-party manufacturers for certain components, increasing the risk of supply shortages [278]. - Global supply chain issues, such as semiconductor shortages, could lead to production delays and increased costs [288]. Management and Operational Challenges - The company may face significant challenges in managing growth, which could adversely affect operations and result in increased costs, product quality issues, and customer service challenges [153]. - The company is currently not receiving reimbursement for its at-home COVID-19 tests from federal or state healthcare programs, which may limit market opportunity [186]. - The sales cycle with institutional customers is lengthy and variable, making revenue forecasting challenging [169]. - The company is highly dependent on its senior management team, and the loss of key personnel could materially impact its business [208]. Intellectual Property and Legal Risks - The strength of the company's patent protection may be challenged, affecting its ability to prevent competitors from commercializing similar technologies [290]. - The company faces potential challenges to its patents, which, if found invalid or unenforceable, could materially affect its business operations [303]. - The diagnostic testing industry is characterized by intellectual property litigation, which could lead to costly legal proceedings and divert management's focus from core business activities [307]. - The company has not conducted a comprehensive freedom to operate analysis, which may leave it unaware of existing patents that could impair its ability to commercialize its products [309]. Cybersecurity and Data Risks - The company depends on information systems for efficient operations; disruptions could harm business performance and financial condition [228]. - Security breaches and data loss could compromise sensitive information, leading to significant legal and financial exposure [232]. - The company faces ongoing cybersecurity threats that could disrupt operations and harm its competitive position [233]. - Cybersecurity threats are evolving, and the company may need to invest significantly in protective measures to mitigate risks associated with data breaches [237]. Future Outlook and Strategic Considerations - The company anticipates fluctuations in customer demand based on seasonality and general expectations around COVID-19, which may lead to inaccurate inventory forecasts and potential write-downs [191]. - The company may consider raising additional capital to fund operations, develop the Cue Integrated Care Platform, and expand operations [256]. - The company may pursue acquisitions or investments in complementary businesses, but integration challenges could dilute shareholder value and disrupt operations [252]. - The company expects to face increased expenses and management diversion due to international expansion risks, including regulatory compliance and market penetration challenges [243].